|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
6,530,000 |
Market
Cap: |
1.38(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.133 - $3.05 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nuwellis is a medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow systems. The Aquadex SmartFlow system is indicated for temporary (up to eight hours) or extended (longer than eight hours in patients who require hospitalization) use in adult and pediatric patients weighing 20kg or more whose fluid overload is unresponsive to medical management, including diuretics.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
4,098 |
Total Buy Value |
$0 |
$0 |
$0 |
$19,629 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Oleson Kimberly |
SVP, Clinical Affairs |
|
2015-04-01 |
4 |
D |
$4.26 |
$1,189 |
D/D |
(279) |
4,368 |
|
- |
|
Oleson Kimberly |
SVP, Clinical Affairs |
|
2015-03-01 |
4 |
D |
$5.75 |
$1,604 |
D/D |
(279) |
4,647 |
|
- |
|
Rosa David A |
Chief Executive Officer |
|
2015-03-01 |
4 |
D |
$5.75 |
$30,050 |
D/D |
(5,226) |
145,717 |
|
- |
|
Wade Molly |
Vice President |
|
2015-03-01 |
4 |
D |
$5.75 |
$3,490 |
D/D |
(607) |
15,751 |
|
- |
|
Kridner Debra |
Exec VP, Regulatory Affairs |
|
2015-03-01 |
4 |
D |
$5.75 |
$3,203 |
D/D |
(557) |
28,285 |
|
- |
|
Kridner Debra |
Exec VP, Regulatory Affairs |
|
2015-02-01 |
4 |
D |
$4.98 |
$2,774 |
D/D |
(557) |
28,842 |
|
- |
|
Wade Molly |
Vice President |
|
2015-02-01 |
4 |
D |
$4.98 |
$3,023 |
D/D |
(607) |
16,358 |
|
- |
|
Rosa David A |
Chief Executive Officer |
|
2015-02-01 |
4 |
D |
$4.98 |
$26,025 |
D/D |
(5,226) |
150,943 |
|
- |
|
Oleson Kimberly |
SVP, Clinical Affairs |
|
2015-02-01 |
4 |
D |
$4.98 |
$1,389 |
D/D |
(279) |
4,926 |
|
- |
|
Wade Molly |
Vice PresidentOfficer |
|
2015-01-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,965 |
|
- |
|
Mathiesen Jeffrey S |
Chief Financial Officer |
|
2015-01-01 |
4 |
D |
$4.24 |
$4,041 |
D/D |
(953) |
37,223 |
|
- |
|
Kridner Debra |
Exec VP, Regulatory Affairs |
|
2015-01-01 |
4 |
D |
$4.24 |
$2,362 |
D/D |
(557) |
29,399 |
|
- |
|
Rosa David A |
Chief Executive Officer |
|
2015-01-01 |
4 |
D |
$4.24 |
$22,158 |
D/D |
(5,226) |
156,170 |
|
- |
|
Peters William S |
CTO & Medical Director |
|
2015-01-01 |
4 |
D |
$4.24 |
$2,883 |
D/D |
(680) |
33,309 |
|
- |
|
Oleson Kimberly |
SVP, Clinical Affairs |
|
2015-01-01 |
4 |
D |
$4.24 |
$1,183 |
D/D |
(279) |
5,205 |
|
- |
|
Rosa David A |
Chief Executive Officer |
|
2014-12-01 |
4 |
D |
$4.52 |
$23,622 |
D/D |
(5,226) |
161,396 |
|
- |
|
Mathiesen Jeffrey S |
Chief Financial Officer |
|
2014-12-01 |
4 |
D |
$4.52 |
$4,308 |
D/D |
(953) |
38,176 |
|
- |
|
Peters William S |
CTO & Medical Director |
|
2014-12-01 |
4 |
D |
$4.52 |
$3,074 |
D/D |
(680) |
33,989 |
|
- |
|
Oleson Kimberly |
SVP, Clinical Affairs |
|
2014-12-01 |
4 |
D |
$4.52 |
$1,261 |
D/D |
(279) |
5,484 |
|
- |
|
Kridner Debra |
Exec VP, Regulatory Affairs |
|
2014-12-01 |
4 |
D |
$4.52 |
$2,518 |
D/D |
(557) |
29,956 |
|
- |
|
Peters William S |
CTO & Medical Director |
|
2014-11-01 |
4 |
D |
$4.85 |
$3,298 |
D/D |
(680) |
34,669 |
|
- |
|
Kridner Debra |
Exec VP, Regulatory Affairs |
|
2014-11-01 |
4 |
D |
$4.85 |
$2,701 |
D/D |
(557) |
30,513 |
|
- |
|
Rosa David A |
Chief Executive Officer |
|
2014-11-01 |
4 |
D |
$4.85 |
$25,346 |
D/D |
(5,226) |
166,622 |
|
- |
|
Oleson Kimberly |
SVP, Clinical Affairs |
|
2014-11-01 |
4 |
D |
$4.85 |
$1,353 |
D/D |
(279) |
5,763 |
|
- |
|
Mathiesen Jeffrey S |
Chief Financial Officer |
|
2014-11-01 |
4 |
D |
$4.85 |
$4,622 |
D/D |
(953) |
39,129 |
|
- |
|
142 Records found
|
|
Page 4 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|